105 related articles for article (PubMed ID: 3026237)
1. DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs.
Spadari S; Pedrali-Noy G; Focher F; Montecucco A; Bordoni T; Geroni C; Giuliani FC; Ventrella G; Arcamone F; Ciarrocchi G
Anticancer Res; 1986; 6(5):935-40. PubMed ID: 3026237
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
Haldane A; Finlay GJ; Baguley BC
Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
[TBL] [Abstract][Full Text] [Related]
4. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
Arcamone F
Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
[TBL] [Abstract][Full Text] [Related]
5. 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.
Basnet A; Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jahng Y; Na Y; Cho WJ; Kwon Y; Lee CS; Lee ES
Bioorg Med Chem Lett; 2010 Jan; 20(1):42-7. PubMed ID: 19954977
[TBL] [Abstract][Full Text] [Related]
6. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
7. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of new xanthone analogues and their biological activity test--cytotoxicity, topoisomerase II inhibition, and DNA cross-linking study.
Woo S; Jung J; Lee C; Kwon Y; Na Y
Bioorg Med Chem Lett; 2007 Mar; 17(5):1163-6. PubMed ID: 17194586
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
11. Amidine analogues of melphalan: synthesis, cytotoxic activity, and DNA binding properties.
Bielawska A; Bielawski K; Anchim T
Arch Pharm (Weinheim); 2007 May; 340(5):251-7. PubMed ID: 17458920
[TBL] [Abstract][Full Text] [Related]
12. Structural analysis of isosteviol and related compounds as DNA polymerase and DNA topoisomerase inhibitors.
Mizushina Y; Akihisa T; Ukiya M; Hamasaki Y; Murakami-Nakai C; Kuriyama I; Takeuchi T; Sugawara F; Yoshida H
Life Sci; 2005 Sep; 77(17):2127-40. PubMed ID: 15935396
[TBL] [Abstract][Full Text] [Related]
13. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(12):1919-29. PubMed ID: 9191970
[TBL] [Abstract][Full Text] [Related]
15. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
16. Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity.
Kim JS; Gatto B; Yu C; Liu A; Liu LF; LaVoie EJ
J Med Chem; 1996 Feb; 39(4):992-8. PubMed ID: 8632422
[TBL] [Abstract][Full Text] [Related]
17. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
[TBL] [Abstract][Full Text] [Related]
18. 2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong BS; Jeong TC; Lee CS; Lee ES
Bioorg Med Chem; 2007 Jul; 15(13):4351-9. PubMed ID: 17493824
[TBL] [Abstract][Full Text] [Related]
19. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
20. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]